NCT05904327 (CIRCOS) is a clinical trial in Oropharynx Squamous Cell Carcinoma, sponsored by Region Örebro County.

Who is sponsoring NCT05904327?

NCT05904327 is sponsored by Region Örebro County.

What condition does NCT05904327 study?

NCT05904327 studies Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma.

Is NCT05904327 still recruiting?

NCT05904327 is currently active, enrolled. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05904327: CIRCOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Biomarkers in Oropharyngeal Cancers

Active, enrolled Last updated 15 June 2023

What this trial tests

trial in Oropharynx Squamous Cell Carcinoma in 130 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2020

Primary endpoint
31 March 2028

31 March 2028

Quick facts

Lead sponsor	Region Örebro County
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	130
Start date	1 December 2020
Primary completion	31 March 2028
Estimated completion	31 March 2028
Sites	1 location across Sweden

Conditions studied

Oropharynx Squamous Cell Carcinoma — all drugs for Oropharynx Squamous Cell Carcinoma →
Oropharynx Cancer — all drugs for Oropharynx Cancer →
Tonsillar Cancer — all drugs for Tonsillar Cancer →
Base of the Tongue Carcinoma — all drugs for Base of the Tongue Carcinoma →

Sponsor

Region Örebro County — full company profile →

Who can join

Eligibility, any sex, with Oropharynx Squamous Cell Carcinoma or Oropharynx Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck. The main questions it aims to answer are: * Can ctHPV-DNA be used for treatment evaluation in HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck? * Can circulating HPV-DNA be used as a biomarker for recurrent disease during surveillance? Participants will be asked to leave plasma samples at diagnose, at the end of treatment and at every clinical follow-up. The patients are there own controls.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Sensitive and Specific Droplet Digital PCR Assays for Circulating Tumor HPV DNA: Development, Validation, and Clinical Application in HPV-Associated Cancers.
Qvick A, Andersson E, Oldaeus Almerén A, Waenerlund M, et al · · 2024 · cited 11× · PMID 39325260 · DOI 10.1007/s40291-024-00743-9
Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV-Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study.
Almerén AO, Waenerlund M, Landström F, von Beckerath M, et al · · 2025 · cited 6× · PMID 40260766 · DOI 10.1111/coa.14317
Epithelial‑derived head and neck squamous tumourigenesis (Review).
Shirima CA, Bleotu C, Spandidos DA, El-Naggar AK, et al · · 2024 · cited 2× · PMID 39219259 · DOI 10.3892/or.2024.8800
The Value of Circulating Tumor HPV DNA in Head and Neck Squamous Cell Cancer: A Review.
Dok R, Nuyts S, Lopez F, Bradford C, et al · · 2025 · PMID 41226001 · DOI 10.3390/diagnostics15212708

Verify or expand the search:

Other recruiting trials for Oropharynx Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
NCT05582122 — SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Thera · Phase 2 · recruiting
NCT06088381 — Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) · Phase 2 · recruiting
NCT05278039 — Training Swallowing Initiation During Expiration · NA · recruiting

Other Region Örebro County trials

Trials by the same sponsor.

NCT07406750 — Hemodynamic Venous Congestion Ultrasound (VExUS) by ICU Nurses in Sepsis Patients. · not yet recruiting
NCT07334132 — General Anaesthesia vs Spinal Anaesthesia: Patient Outcomes and Success in Outpatient Primary Total Knee and Hip Arthrop · Phase 4 · not yet recruiting
NCT07158138 — A Digitally Distributed Yoga Intervention in Prostate Cancer Rehabilitation : Protocol for a Randomized Controlled Trial · NA · not yet recruiting
NCT07206147 — Physical Exercise as Treatment Post-stroke Fatigue - a Feasibilty Study. · NA · not yet recruiting
NCT07378566 — Intervention to Master Complex Fall Risk Situations in Persons With Multiple Sclerosis (STAR) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05904327 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Region Örebro County
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing